Senior Director, Clinical Development - Dermatology (MD)

Gilead Sciences, Inc.

Where
Hybrid in United States - California - Foster City
Pay
$302K a year

Posted 22 days ago· Checked live at Gilead Sciences, Inc. 4 days ago

Stale: open 22 daysUp for more than two weeks. It may already be filled.

See how you score for this job

One sentence and your resume. We score it against what Gilead Sciences, Inc. asks for, line by line.

See my score
Is this job still open?
Yes. We checked it live on Gilead Sciences, Inc.'s own hiring page 4 days ago.
What is the job?
At Gilead, we’re creating a healthier world for all people. For more than 35 years, we’ve tackled diseases such as HIV, viral hepatitis, COVID-19 and cancer – working relentlessly to develop therapies that help improve lives and to ensure access to these therapies across the globe.
What does it pay?
$302K a year, as the posting states.
Our verdict
Stale. Up for more than two weeks. It may already be filled.

What the job is

At Gilead, we’re creating a healthier world for all people. For more than 35 years, we’ve tackled diseases such as HIV, viral hepatitis, COVID-19 and cancer – working relentlessly to develop therapies that help improve lives and to ensure access to these therapies across the globe.

Key Responsibilities

  • Provide clinical and scientific leadership for one or more inflammation development programs, with opportunities spanning dermatologic, respiratory, and other immune-mediated diseases.
  • Lead development and continual refinement of Clinical Development Plans (CDPs), including indication strategy, target populations, clinical sequencing, differentiation strategy, success criteria, and key development decisions.
  • Lead the strategy, design, initiation, execution, and interpretation of Phase 2 clinical development programs, including proof-of-concept and dose-ranging studies, with an eye toward Phase 3 and registration.
  • Own key elements of Phase 2 program development, including clinical strategy, protocol development, patient population, endpoints, dose and regimen selection, and medical input into site and investigator selection.
  • Provide medical and scientific leadership during study start-up and execution, including investigator and site selection strategy, site initiation, investigator engagement, enrollment, protocol interpretation, and ongoing assessment of study conduct.
  • Use emerging Phase 2 data to refine the development strategy and prepare successful programs for transition into Phase 3 and registrational development.
  • Translate complex immunology, human genetics, translational science, and disease biology into testable clinical hypotheses and development strategies.
  • Integrate clinical, translational, biomarker, pharmacologic, competitive, and emerging external data to inform asset and portfolio strategy.
  • Provide senior medical leadership for protocols, eligibility criteria, endpoints, safety monitoring, dose selection, benefit-risk assessment, and interpretation of clinical data.
  • Apply a strong understanding of dermatologic disease biology and clinical development to programs in areas such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and related immune-mediated diseases, while contributing broadly across the inflammation portfolio.
  • Identify opportunities for differentiation based on mechanism, patient population, clinical endpoints, treatment setting, and evolving standards of care.
  • Partner closely and proactively with Clinical Operations, Biostatistics, Clinical Pharmacology, Translational Medicine, Research, Regulatory Affairs, Safety, Medical Affairs, and Commercial colleagues.
  • Provide influential Clinical Development leadership on cross-functional asset teams and help drive program strategy, development recommendations, and governance decisions.
  • Develop productive scientific relationships with investigators, external experts, and key opinion leaders, and use these relationships to refine clinical strategy and evidence-generation plans.
  • Provide clinical leadership for regulatory strategy and health authority interactions across Phase 2 development and the transition to Phase 3, including end-of-Phase 2 discussions and preparation or review of clinical components of regulatory submissions.
  • Mentor and develop clinical scientists and physicians and contribute to a strong scientific and clinical development culture.

Basic Qualifications

MD, 10+ years of relevant clinical, scientific, and/or drug-development experience in industry, academia, or a combination of both, including substantial experience in clinical development and demonstrated leadership in establishing and executing Phase 2 clinical development programs, with experience contributing to or leading Phase 3 development.

Preferred Qualifications

  • Direct experience developing Phase 2 clinical strategy and protocols, initiating and conducting Phase 2 interventional trials, and interpreting Phase 2 data to inform Phase 3 development strategy.
  • Experience providing clinical input into investigator and site selection, study initiation, and ongoing medical leadership during trial execution.
  • Expertise in immunology, inflammation, dermatology, or immune-mediated disease.
  • Strong command of clinical trial design, endpoints, statistics, safety assessment, dose selection, benefit-risk evaluation, and drug-development principles.
  • Demonstrated ability to critically evaluate emerging biological and clinical data and translate those data into clear development decisions.
  • Demonstrated success leading through multidisciplinary teams and influencing senior stakeholders without direct authority.
  • Strong written and verbal communication skills, including communicating complex scientific concepts and development recommendations clearly to senior leaders and non-specialist audiences. Clinical training, board certification, or substantial drug-development expertise in dermatology, allergy/immunology, rheumatology, pulmonary medicine, or a related specialty.
  • Clinical development experience in atopic dermatitis, hidradenitis suppurativa, psoriasis, or related inflammatory diseases; experience in asthma, COPD, or other immune-mediated diseases is also relevant.
  • Experience building Phase 2 programs from strategy and protocol development through study initiation and execution, and advancing programs from Phase 2 proof-of-concept or dose finding into Phase 3.
  • Experience with global Phase 3 programs and regulatory interactions supporting late-stage development.
  • Experience developing small molecules, biologics, and/or novel targeted modalities in immune-mediated disease.
  • Experience developing and applying pharmacodynamic, translational, patient-selection, or disease biomarkers.
  • Established relationships with investigators and external scientific experts in dermatology, immunology, or inflammatory disease.

For additional benefits information, visit

https://www.gilead.com/careers/compensation-benefits-and-wellbeing

  • Eligible employees may participate in benefit plans, subject to the terms and conditions of the applicable plans.